Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials.
Publication
, Journal Article
Boersma, E; Harrington, RA; Van de Werf, FV; Armstrong, PW; Simes, J; Hasselblad, V; Simoons, ML
Published in: CIRCULATION
October 23, 2001
Duke Scholars
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 23, 2001
Volume
104
Issue
17
Start / End Page
782 / 782
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Boersma, E., Harrington, R. A., Van de Werf, F. V., Armstrong, P. W., Simes, J., Hasselblad, V., & Simoons, M. L. (2001). Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials. CIRCULATION, 104(17), 782–782.
Boersma, E., R. A. Harrington, F. V. Van de Werf, P. W. Armstrong, J. Simes, V. Hasselblad, and M. L. Simoons. “Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials.” CIRCULATION 104, no. 17 (October 23, 2001): 782–782.
Boersma E, Harrington RA, Van de Werf FV, Armstrong PW, Simes J, Hasselblad V, et al. Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials. CIRCULATION. 2001 Oct 23;104(17):782–782.
Boersma, E., et al. “Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials.” CIRCULATION, vol. 104, no. 17, LIPPINCOTT WILLIAMS & WILKINS, Oct. 2001, pp. 782–782.
Boersma E, Harrington RA, Van de Werf FV, Armstrong PW, Simes J, Hasselblad V, Simoons ML. Acute coronary syndrome patients benefit from platelet glycoprotein IIb/IIIa inhibition as part of an initially medical treatment strategy: Results of a meta-analysis of phase III randomized trials. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2001 Oct 23;104(17):782–782.
Published In
CIRCULATION
ISSN
0009-7322
Publication Date
October 23, 2001
Volume
104
Issue
17
Start / End Page
782 / 782
Publisher
LIPPINCOTT WILLIAMS & WILKINS
Related Subject Headings
- Cardiovascular System & Hematology
- 4207 Sports science and exercise
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology